Visitor preview: 5 stories per page Create my free account
Events database

Stroke survivors get FDA-approved daily pill shown to cut repeat risk by 26%

Sunharbo (asundexian) is the first FDA-approved factor XIa inhibitor for secondary stroke prevention, but key limitations and risks do remain.

Advanced analysis (spheres, detailed sources, paid analyses)
Event date
exact date
Coverage
5 outlets · 5 articles
first · latest
Reporting countries
Australia
English
Countries concerned
United Kingdom
Health · intensity 1.0 · tone 0.00
In 5 seconds

Covered mainly by the Global South sphere (80%); silent in Sino-Russian & BRICS, Arab-Muslim world.

Western 20%Sino-Russian & BRICS 0%Arab-Muslim world 0%Global South 80%

Global sphere reading. The left / centre / right reading is shown in the coverage analysis below.

In 30 seconds
  • Confirmed by 5 outlets in 2 countries.
  • Ignored by Sino-Russian & BRICS, Arab-Muslim world.
  • Propagation: first reported by foxnews.com (Australia), . 4 outlets republished 1 headline word for word.

Headline clash across the four spheres

Western
Sino-Russian & BRICS

No outlet in this sphere covers the event: blind spot.

Arab-Muslim world

No outlet in this sphere covers the event: blind spot.

Global South

Coverage analysis

Analyzing coverage…

Event sources

  1. Stroke survivors get FDA-approved daily pill shown to cut repeat risk by 26%
    foxnews.comAustralieAustralia → United StatesEnglish
  2. FDA approves daily pill shown to cut repeat stroke risk by 26%
    fox5atlanta.comGeorgiaGeorgia → United StatesUnknown language
  3. FDA approves daily pill shown to cut repeat stroke risk by 26%
    fox4news.comGeorgiaGeorgia → Unknown countryEnglish
  4. FDA approves daily pill shown to cut repeat stroke risk by 26%
    fox13news.comGeorgiaGeorgia → United StatesEnglish
  5. FDA approves daily pill shown to cut repeat stroke risk by 26%
    livenowfox.comGeorgiaGeorgia → United StatesEnglish